Pioglitazone, a pharmacological agonist of the nuclear receptor PPARγ, acts as an insulin sensitizer and is used to treat T2D, a risk factor for AD (Ahmadian et al., 2013; Arnold et al., 2018; Biessel and Despa, 2018). The gene discussed is PPARG; the disease is type 2 diabetes mellitus.